Haematocrit Blood Test

A haematocrit blood test can help you:

• Detect anaemia when haematocrit is too low, which may explain fatigue, shortness of breath, palpitations, or reduced performance.
• Identify high red cell levels polycythaemia when haematocrit is too high, which can make blood thicker and raise clot and cardiovascular risk.
• Monitor blood counts in people with kidney disease, heart or lung disease, heavy menstrual bleeding, inflammatory bowel disease, or athletes using altitude training.
• Track response to iron, B12, or folate treatment, or to therapies that modify red cell production.
• Provide context when interpreting oxygen delivery, blood pressure, and cardiovascular risk.

Haematocrit literally means "to separate blood" and describes the fraction of blood volume that consists of red blood cells. In modern analysers, haematocrit is usually calculated rather than directly spun, using:

• Red blood cell count.
• Mean cell volume MCV.

It is reported as:

• A fraction or ratio for example 0.42 L/L.
• Or as a percentage for example 42 percent.

Haematocrit always sits alongside haemoglobin and red blood cell count in a full blood count FBC.

Haematocrit reflects how concentrated your red blood cells are:

• A low haematocrit means a smaller proportion of your blood volume is red cells, consistent with anaemia or overhydration.
• A high haematocrit means a larger proportion is red cells, which can occur in polycythaemia, chronic low oxygen states, or dehydration.

Because haematocrit is influenced by both red cell mass and plasma volume, it is most useful when interpreted alongside haemoglobin, red cell indices, hydration status, and clinical context.

Haematocrit matters because:

• Red blood cells carry haemoglobin, which transports oxygen to your tissues. Too few red cells limit oxygen delivery and can reduce energy, endurance, and cognitive function.
• Too many red cells increase blood viscosity thickness, which can slow flow, strain the heart, and increase risk of clots, heart attack, and stroke, especially when combined with other risk factors.
• Haematocrit changes in chronic lung disease, high altitude exposure, kidney disease, and some tumours reflect how your body is adapting to or being driven by oxygen and hormone signals.

In preventive and performance health, haematocrit sits alongside haemoglobin, ferritin, iron studies, and cardiometabolic markers to show how well your blood supports both day to day function and long term risk.

These red cell markers are closely related but distinct:

• Haematocrit HCT is the percentage of blood volume occupied by red blood cells.
• Haemoglobin Hb is the concentration of oxygen carrying protein in your blood.
• Red blood cell count RBC is the number of red cells per unit volume.
• Mean cell volume MCV is the average size of each red blood cell.

Typical patterns:

• Iron deficiency anaemia: low haematocrit, low haemoglobin, low MCV small red cells, often with low ferritin.
• B12 or folate deficiency: low haematocrit, low haemoglobin, high MCV large red cells.
• Polycythaemia: high haematocrit and haemoglobin, often with normal MCV, and symptoms related to thick blood.

Haematocrit is influenced by red cell production, destruction, loss, and plasma volume. Key factors include:

1. Iron, B12, folate, and nutrient status

• Iron deficiency from low intake, poor absorption, or blood loss reduces red cell production and lowers haematocrit.
• Vitamin B12 or folate deficiency impairs red cell DNA synthesis, causing anaemia with low haematocrit.
• Very low protein or calorie intake can also affect red cell production over time.

2. Blood loss and red cell destruction

• Heavy menstrual bleeding, gastrointestinal bleeding, surgery, trauma, or frequent blood donation can reduce haematocrit.
• Haemolytic anaemias, where red cells are destroyed faster than they are made, also lower haematocrit.

3. Kidney function and erythropoietin

• The kidneys produce erythropoietin EPO, which stimulates red cell production.
• Chronic kidney disease often leads to lower haematocrit and anaemia.
• Some kidney and other tumours can overproduce EPO, raising haematocrit.

4. Lung and heart disease, altitude, and lifestyle

• Chronic lung disease, sleep apnoea, congenital heart disease, and smoking can lower blood oxygen and drive the body to make more red cells, raising haematocrit.
• Living or training at high altitude increases haematocrit as an adaptation to thinner air.
• Smoking and dehydration often contribute to higher haematocrit on top of other factors.

5. Hydration and plasma volume

• Dehydration reduces plasma volume and concentrates red cells, raising haematocrit.
• Overhydration or fluid overload dilutes red cells and lowers haematocrit.

Reference ranges vary by lab, age, and sex, but in UK adult practice typical haematocrit ranges are:

• Adult men: around 0.40 to 0.52 L/L 40 to 52 percent.
• Adult women: around 0.37 to 0.47 L/L 37 to 47 percent.

Broad interpretation:

• Low haematocrit suggests anaemia or dilution, and prompts assessment of haemoglobin, red cell indices, iron studies, B12, folate, kidney function, and sources of blood loss or inflammation.
• High haematocrit raises the possibility of polycythaemia, chronic hypoxia, dehydration, smoking, or rare EPO driven conditions and is assessed alongside haemoglobin, EPO, oxygen saturation, and sometimes JAK2 mutation testing.

Fasting is not usually needed for a haematocrit test.

You may be asked to:

• Fast if haematocrit is measured within a fasting metabolic or lipid panel.
• Avoid heavy exercise, extreme dehydration, or large changes in fluid intake right before the test so results reflect your usual baseline.

Managing haematocrit is about optimising red cell production and plasma volume and treating underlying causes.

For low haematocrit anaemia, clinician guided strategies may include:

• Investigating and treating sources of blood loss such as heavy periods or gastrointestinal bleeding.
• Correcting iron, B12, or folate deficiency with diet, supplements, or injections, and addressing causes of poor absorption.
• Treating chronic kidney disease, inflammatory conditions, or bone marrow disorders that impair red cell production.
• Using erythropoiesis stimulating agents in selected CKD or oncology settings, with careful monitoring.

For high haematocrit polycythaemia or apparent erythrocytosis, strategies may include:

• Checking for dehydration, smoking, sleep apnoea, chronic lung or heart disease, and adjusting lifestyle and treatments.
• Investigating for polycythaemia vera and other myeloproliferative neoplasms when counts are substantially raised.
• Using venesection controlled blood removal and low dose aspirin in appropriate cases to reduce haematocrit and clot risk.